0000950123-24-006286 Sample Contracts
MAZE THERAPEUTICS, INC. PACIFIC WESTERN BANK LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of June 27, 2022, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and MAZE THERAPEUTICS, INC., a Delaware corporation (“Borrower”).
LICENSE AGREEMENTLicense Agreement • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
MAZE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 8, 2021Investors’ Rights Agreement • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 8, 2021, by and among Maze Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the “Investors”.
MAZE THERAPEUTICS, INC. ADVISOR AGREEMENTAdvisor Agreement • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS ADVISOR AGREEMENT (this “Agreement”) is made and entered into as of July 1, 2021 by and between Richard Scheller, an individual (“Advisor”), whose address is set forth on the last page below, and Maze Therapeutics, Inc., a Delaware corporation (the “Company”), whose address is set forth on the last page below.
MAZE THERAPEUTICS, INC. SUBORDINATED CONVERTIBLE PROMISSORY NOTEConvertible Note • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Note has been issued pursuant to that certain Convertible Note Purchase Agreement, dated as of December 15, 2023 (as may be amended from time to time, the “Purchase Agreement”), by and among the Company, the original holder of this Note and certain other investors and is subject to the provisions of the Purchase Agreement. This note is subordinated to Pacific Western Bank, a California state-chartered bank, pursuant to the Subordination Agreement (as defined in the Purchase Agreement) The following is a statement of the rights of Holder and the terms and conditions to which this Note is subject, and to which the Holder hereof, by the acceptance of this Note, agrees.
CONSULTING AGREEMENTConsulting Agreement • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Consulting Agreement (the “Agreement”) is made and entered into by and between Maze Therapeutics, Inc. a Delaware corporation, having a place of business at 131 Oyster Point Blvd, Suite 200, South San Francisco, CA 94080 (the “Company”), and Charles Homcy, an individual (“Consultant”), having a primary address of effective as of November 1, 2019 (“Effective Date”).